Redefining Early Stage Investments (RESI) Conference: Corporate VCs & Strategic Investment Panel

7 Jan

By Christine A. Wu, Research Analyst, LSN

chrsitine

At LSN’s RESI San Francisco Conference next Tuesday, January 12th, the Corporate VC & Strategic Investment panel will focus on how major pharmaceutical companies evaluate and invest in early stage life science companies, both through corporate venture capital arms and internal investment units.

In this panel, corporate VC and major pharmaceutical investors will discuss the types of companies they’re interested in investing in, and how they structure these opportunities to achieve their strategic aims. Panelists will provide advice on how entrepreneurs can engage with a corporate investor, and what to expect from an investment relationship with a large pharmaceutical company.

Moderated by Edward Hu, CFO & CIO of WuXi AppTec, the audience will hear from:

  • Carolyn E. Green, Executive Director, Strategic Investments, Worldwide R&D, Pfizer
  • Geeta Vemuri, Vice President, Head, Baxalta Ventures
  • Hakan Goker, Senior Investment Director, MS Ventures
  • Ilan Zipkin, Senior Investment Director, Takeda Ventures

If you’re a fundraising entrepreneur seeking strategic investments with a major pharmaceutical company, this panel is not one you want to miss. RESI San Francisco is already the largest RESI yet with over 700 attendees. This will be a great opportunity to expand your network in the life science space, so register now before it’s too late.

RESI-San-Francisco-2016

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: